An open-label, multi-center, 6-week, sequential cohort study designed to determine the safety and tolerability of two dose ranges of BL-1020 in hospitalized subjects with chronic schizophrenia or schizo-affective disorder.

Trial Profile

An open-label, multi-center, 6-week, sequential cohort study designed to determine the safety and tolerability of two dose ranges of BL-1020 in hospitalized subjects with chronic schizophrenia or schizo-affective disorder.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jul 2009

At a glance

  • Drugs BL 1020 (Primary)
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Sep 2008 Planned end date identified as 1 Dec 2007 from ClinicalTrials.gov.
    • 15 Sep 2008 Status changed from recruiting to completed according to ClinicalTrials.gov.
    • 05 Feb 2008 Interim results reported in a BioLineRx media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top